This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie Secures FDA Approval for Endometriosis Drug Elagolix
by Zacks Equity Research
AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.
Company News For Jul 25, 2018
by Zacks Equity Research
Companies In The News are: HOG,BIIB,LLY,WHR
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco
by Zacks Equity Research
Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.
Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 14.50% and 4.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Tops Q2 Earnings & Sales, Ups 2018 View
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both earnings and sales in Q2 and raised the guidance for 2018. Shares rose in pre-market trading.
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label
by Zacks Equity Research
Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK).
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).
Pfizer to Defer Price Increases After Discussion With Trump
by Zacks Equity Research
Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study
by Zacks Equity Research
Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern